Mainz Biomed BV (MYNZ) - Net Assets
Based on the latest financial reports, Mainz Biomed BV (MYNZ) has net assets worth $641.60K USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.33 Million) and total liabilities ($4.69 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore Mainz Biomed BV operating cash flow efficiency to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $641.60K |
| % of Total Assets | 12.04% |
| Annual Growth Rate | N/A |
| 5-Year Change | -89.91% |
| 10-Year Change | N/A |
| Growth Volatility | 94.45 |
Mainz Biomed BV - Net Assets Trend (2019–2025)
This chart illustrates how Mainz Biomed BV's net assets have evolved over time, based on quarterly financial data. Also explore Mainz Biomed BV asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Mainz Biomed BV (2019–2025)
The table below shows the annual net assets of Mainz Biomed BV from 2019 to 2025. For live valuation and market cap data, see Mainz Biomed BV (MYNZ) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $641.60K | -89.39% |
| 2024-12-31 | $6.05 Million | +86.09% |
| 2023-12-31 | $3.25 Million | -76.95% |
| 2022-12-31 | $14.10 Million | +121.60% |
| 2021-12-31 | $6.36 Million | +332.03% |
| 2020-12-31 | $-2.74 Million | -40.57% |
| 2019-12-31 | $-1.95 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Mainz Biomed BV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10053441000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $107.82K | 16.80% |
| Other Comprehensive Income | $-617.65K | -96.27% |
| Other Components | $106.05 Million | 16529.58% |
| Total Equity | $641.60K | 100.00% |
Mainz Biomed BV Competitors by Market Cap
The table below lists competitors of Mainz Biomed BV ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Chia Yi Steel Co Ltd
TWO:2067
|
$9.50 Million |
|
STAK Inc. Ordinary Shares
NASDAQ:STAK
|
$9.51 Million |
|
ECSTELECOM Co. Ltd
KQ:067010
|
$9.51 Million |
|
Yunhong Green CTI Ltd.
NASDAQ:YHGJ
|
$9.51 Million |
|
ECOUP OYJ EO 1
F:62H
|
$9.49 Million |
|
Enjoy S.A
SN:ENJOY
|
$9.48 Million |
|
BLB Limited
NSE:BLBLIMITED
|
$9.48 Million |
|
Nala Digital Commerce Ltd
TA:NALA
|
$9.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mainz Biomed BV's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,046,543 to 641,600, a change of -5,404,943 (-89.4%).
- Net loss of 16,210,718 reduced equity.
- New share issuances of 8,248,261 increased equity.
- Other comprehensive income decreased equity by 27,655,729.
- Other factors increased equity by 30,213,243.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-16.21 Million | -2526.61% |
| Share Issuances | $8.25 Million | +1285.58% |
| Other Comprehensive Income | $-27.66 Million | -4310.43% |
| Other Changes | $30.21 Million | +4709.05% |
| Total Change | $- | -89.39% |
Book Value vs Market Value Analysis
This analysis compares Mainz Biomed BV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.09x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.17 | $0.76 | x |
| 2020-12-31 | $-0.49 | $0.76 | x |
| 2021-12-31 | $0.88 | $0.76 | x |
| 2022-12-31 | $1.00 | $0.76 | x |
| 2023-12-31 | $0.20 | $0.76 | x |
| 2024-12-31 | $6.24 | $0.76 | x |
| 2025-12-31 | $0.11 | $0.76 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mainz Biomed BV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2526.61%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3018.31%
- • Asset Turnover: 0.10x
- • Equity Multiplier: 8.30x
- Recent ROE (-2526.61%) is below the historical average (-580.77%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -340.11% | 0.39x | 0.00x | $-762.03K |
| 2020 | 0.00% | -118.91% | 0.73x | 0.00x | $-312.74K |
| 2021 | -183.77% | -2024.79% | 0.06x | 1.58x | $-12.33 Million |
| 2022 | -187.66% | -4992.24% | 0.03x | 1.44x | $-27.86 Million |
| 2023 | -809.29% | -2936.50% | 0.06x | 4.74x | $-26.62 Million |
| 2024 | -358.07% | -2421.80% | 0.07x | 2.19x | $-22.26 Million |
| 2025 | -2526.61% | -3018.31% | 0.10x | 8.30x | $-16.27 Million |
Industry Comparison
This section compares Mainz Biomed BV's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $803,738,043
- Average return on equity (ROE) among peers: -56.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mainz Biomed BV (MYNZ) | $641.60K | 0.00% | 7.30x | $9.49 Million |
| Agilent Technologies Inc (A) | $6.74 Billion | 6.44% | 0.89x | $32.79 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $976.24K | -188.19% | 0.03x | $6.34 Million |
| Applied DNA Sciences Inc (APDN) | $-11.94 Million | 0.00% | 0.00x | $3.99 Million |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $79.44 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $7.42 Million |
| Biocept Inc. (BIOCQ) | $23.69 Million | -75.16% | 1.00x | $262.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $480.11 Million | 1.55% | 0.32x | $3.77 Billion |
| Burning Rock Biotech Ltd (BNR) | $1.16 Billion | -83.85% | 0.37x | $107.26 Million |
| CareDx Inc (CDNA) | $-147.20 Million | 0.00% | 0.00x | $1.00 Billion |
| Check Cap Ltd (CHEK) | $6.23 Million | -221.94% | 0.51x | $9.42 Million |
About Mainz Biomed BV
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes … Read more